RNA (Atrium Therapeutics) Institutional Ownership: 86.64% (As of Jul. 02, 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $13.30
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics Institutional Ownership?

Atrium Therapeutics RNA -0.97% 12 Institutional Ownership is 86.64% as of Jul. 02, 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Atrium Therapeutics's institutional ownership is 86.64%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Atrium Therapeutics's Insider Ownership is 4.27%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Atrium Therapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.

Atrium Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics Institutional Ownership Chart

Atrium Therapeutics Historical Data

The historical data trend for Atrium Therapeutics can be seen below:

2026-02-28 2026-03-31 2026-04-30 2026-05-31
Institutional Ownership 17.88 30.28 29.81 29.85
RNA
12GF Score
Atrium Therapeutics Inc RNA
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 86.64% mean?
Atrium Therapeutics (RNA) has a Institutional Ownership of 86.64% as of Jul. 02, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Atrium Therapeutics and its competitors.
Is Atrium Therapeutics' Institutional Ownership too high?
Atrium Therapeutics' current Institutional Ownership is 86.64%. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Institutional Ownership compare to CNTN and QTTB?
Atrium Therapeutics' Institutional Ownership of 86.64% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current Institutional Ownership is 86.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Institutional Ownership of 86.64%. The current Institutional Ownership is 86.64%. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Institutional Ownership is 86.64% as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.30
Price